A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Recruiting

Phase 3

GuselkumabA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Sponsor:

Janssen Research & Development, LLC

Code:

NCT05923073

Conditions

Crohn's Disease

Eligibility Criteria

Sex: All

Age: 2 - 17

Healthy Volunteers: Not accepted

Interventions

Guselkumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-25. This information was provided to ClinicalTrials.gov by Janssen Research & Development, LLC on 2025-04-03.